Laromustine
Trade name: onrigin
Small moleculeexperimental
Clinical trial activity
15 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00025129)
Timeline
Indications
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)N(N(CCCl)S(C)(=O)=O)S(C)(=O)=O- Mol. weight
- 307.78 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL167691 ↗
Also known as
- 101m
- 101m
- 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-((2-methylamino)carbonyl)hydrazine
- cloretazine
- cloretazine
- cloretazine
- cloretazine
- cloretazine
- laromustine
- laromustine
- laromustine
- laromustine
- laromustine
- onrigin
- onrigin
- onrigin
- vnp40101m
- vnp40101m
- vnp40101m
- vnp 40101m
- vnp-40101m
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00840684 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2009 | Institut Paoli-Calmettes |
| NCT00655395 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2008 | Cornell University, Vion Pharmaceuticals |
| NCT00521859 | Phase 1 | Aug 1, 2007 | University of Texas at Houston, Vion Pharmaceuticals |
| NCT00516282 | Phase 1 | Aug 1, 2007 | Northwestern University, Vion Pharmaceuticals |
| NCT00354276 | Phase 2 | May 1, 2006 | Vion Pharmaceuticals |
| NCT00083187 | Phase 2 | Nov 1, 2005 | University of Texas at Houston, Vion Pharmaceuticals |
| NCT00282022 | Phase 2 | Sep 1, 2005 | Vion Pharmaceuticals |
| NCT00304005 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2005 | Vion Pharmaceuticals |
| NCT00112554 | Phase 3 | Mar 1, 2005 | Vion Pharmaceuticals |
| NCT00098761 | Phase 1 | Feb 1, 2005 | Duke University, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium |
| NCT00098436 | Phase 1 | Sep 1, 2004 | Vion Pharmaceuticals |
| NCT00070538 | Phase 1 | Jun 1, 2003 | National Cancer Institute (NCI), Vion Pharmaceuticals |
| NCT00049699 | Phase 1 | Oct 1, 2002 | Vion Pharmaceuticals |
| NCT00049686 | Phase 1 | Apr 1, 2002 | Vion Pharmaceuticals |
| NCT00025129 | Phase 1 | Mar 1, 2001 | Vion Pharmaceuticals |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vion Pharmaceuticals | For profit | 13 | 10 | 3 | 2001 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2003 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 2 | 2005 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2005 |
8 organizations
Page 1 / 1